| | |  | | | | Record from Web of Science® | | | | | | |
| The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors |
|
|
| Author(s): Reilly RT, Machiels JPH, Emens LA, Ercolini AM, Okoye FI, Lei RY, Weintraub D, Jaffee EM |
| Source: CANCER RESEARCH Volume: 61 Issue: 3 Pages: 880-883 Published: FEB 1 2001 |
| Times Cited: 86 References: 20 |
| Abstract: HER-2/neu (neu) transgenic mice (neu-N mice), which express the nontransforming rat proto-oncogene, demonstrate immunological tolerance to neu that is similar to what is encountered in patients with neu-expressing breast cancer. We have shown previously that a significant increase in neu-specific T cells, but no induction of neu-specific antibody, is seen after neu-specific vaccination in neu-N mice. In contrast, a significant induction of both neu-specific T-cell and antibody responses is found in nontoleragenic FVB/N mice after vaccination. These mice are fully protected from a s.c. challenge with NT cells, a mammary tumor cell line derived from a spontaneous tumor that arose in a neu-N mouse, whereas neu-N mice are not. In this study, we demonstrate that CD4(+) T cell-depleted FVB/N mice show no induction of neu-specific IgG after vaccination and are unable to reject an NT challenge (0 of 10 mice were tumor free). Conversely, the depletion of natural killer cells has no effect on vaccine-mediated tumor rejection (100% of mice were tumor free). In CD8(+) T cell-depleted animals, where vaccine-induced neu-specific IgG titers were normal, NT growth was delayed, but only 10% of mice remained tumor free, demonstrating that neu-specific Ige alone is insufficient for protection from NT challenge. To directly assess the necessity for the combination of neu-specific cellular and humoral immune responses, severe combined immunodeficient mice were given an adoptive transfer of CTLs plus IgG derived from FVB/N mice. Animals that were given CTLs that recognized an irrelevant antigen plus neu-specific IgG developed tumors at a rate similar to CD8+ T cell-depleted FVB/N mice. Animals receiving an adoptive transfer of neu-specific CTLs plus control Ige derived from naive FVB/N mice were only partially protected from NT challenge (50% of animals were tumor free). However, only animals receiving the combination of neu-specific CTLs and neu-specific IgG were fully protected from NT challenge (100% of animals were tumor free). These studies specifically define the immunological requirements for the eradication of neu-expressing tumors in this model system, demonstrating that both cellular and humoral neu-specific responses are necessary for protection from an NT challenge. These data suggest that vaccines optimized to induce maximal T- and B-cell immunity to neu, and possibly to similar putative tumor-rejection antigens, may lead to more potent in vivo antitumor immunity. |
| Document Type: Article |
| Language: English |
| Reprint Address: Jaffee, EM (reprint author), Johns Hopkins Univ, Sch Med, Dept Oncol, Bunting Blaustein Canc Res Bldg,Room 4 M07,1650 O, Baltimore, MD 21231 USA |
Addresses:
1. Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21231 USA
2. Johns Hopkins Univ, Sch Med, Dept Immunol, Baltimore, MD 21231 USA |
| Publisher: AMER ASSOC CANCER RESEARCH, PO BOX 11806, BIRMINGHAM, AL 35202 USA |
| Subject Category: Oncology |
| IDS Number: 403AJ |
| ISSN: 0008-5472 |
|
| | | | | | | | | Record from Web of Science® | | | | | | | | | |